<kuvdh class="emdlbu"></kuvdh>

evo视讯官网

Be the most trusted biotech company

2025-08-28

Henlius Featured at the 2025 Evercore China Biotech Summit
2025-08-25

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
2025-08-22

First Subject Dosed in the US for a Phase 2 International Clinical Trial of Henlius’ PD-L1 ADC HLX43 for NSCLC
2025-08-21

Henlius’ Serplulimab Prescribed for the First Time in Both Europe and India, Marking a Milestone Toward Global Accessibility
2025-08-19

Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum
2025-08-14

Release of the Updated Abstract for Henlius’ PD-L1 ADC HLX43 at 2025 WCLC
2025-08-14

Ten studies on Henlius' innovative products to be showcased at WCLC 2025, Including Three Oral Presentations
2025-08-13

China NMPA Accepts New Drug Application for HLX04-O for Treatment of Ophthalmic Diseases
2025-08-07

Henlius to Initiate a Phase 1 Multicenter Study in US of Its PD-L1 ADC HLX43 for the Treatment of Thymic Carcinoma